NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW – Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 893 shares, a drop of 49.8% from the September 15th total of 1,779 shares. Based on an average daily volume of 2,775 shares, the days-to-cover ratio is presently 0.3 days.
NeuroSense Therapeutics Stock Up 30.3%
NRSNW stock traded up $0.00 during mid-day trading on Wednesday, reaching $0.01. 14,003 shares of the company traded hands, compared to its average volume of 2,439. The company has a fifty day moving average price of $0.06 and a 200-day moving average price of $0.11. NeuroSense Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.54.
NeuroSense Therapeutics Company Profile
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases. The company focuses on conditions with significant unmet medical needs, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease.
Its lead product candidate, PrimeC, is an investigational combination therapy designed to address multiple disease mechanisms associated with ALS. PrimeC combines ciprofloxacin and celecoxib in a proprietary formulation and has been evaluated in clinical studies involving patients with ALS.
Further Reading
- Five stocks we like better than NeuroSense Therapeutics
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
